InterMune Inc. (ITMN)

[ghmm]

These are the Abstracts I found at AASLD:

1- 1871. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics (PK) of Single Ascending Oral Doses of the NS3/4A Protease Inhibitor ITMN 191 in Healthy Subjects. W. Z. Bradford; C. Rubino; S. Porter; A. Forrest; L. M. Blatt; A. A. Patat
2- 1847. Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Patients with the NS3/4A Protease Inhibitor ITMN-191 Leads to Rapid Reductions in Plasma HCV RNA: Results of a Phase 1b Multiple Ascending Dose (MAD) Study. N. Forestier; D. G. Larrey; D. Guyader; P. Marcellin; R. Rouzier; A. A. Patat; W. Z. Bradford; S. Porter; S. Zeuzem
3- 1885. Combination of the NS3/4A Protease Inhibitor ITMN-191 (R7227) with the Active Moiety of the NS5B Inhibitors R1626 or R7128 Enhances Replicon Clearance and Reduces the Emergence of Drug Resistant Variants . H. Tan; S. Rajyaguru; T. Wu; M. McCown; S. Ali; W. Jiang; M. J. Otto; P. A. Furman; I. Najera; K. Klumpp; J. Symons; N. Cammack; L. M. Blatt; S. Seiwert
4- 1861. Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships for ITMN-191 in a Phase 1 Multiple Ascending Dose Trial in Patients with Genotype 1 Chronic Hepatitis C (CHC)Infection . C. Rubino; W. Z. Bradford; A. Forrest; S. Porter; L. M. Blatt; S. Seiwert; S. Zeuzem
5- 898. Interferon gamma-1b (IFN-γ1b) and inhibitors of the hepatitis B virus (HBV) polymerase display additive to synergistic effects in cell culture models: potential implications for treatment . L. M. Blatt; H. Tan; K. Kossen; S. Seiwert
6- 1580. Interferon Gamma (IFNg) Induces the Release of High Mobility Group Box (HMGB)1 from Rat Hepatocytes through JAK- and JNK-dependent signaling pathways . P. Pan; J. Cardinal; D. A. Geller; A. Tsung
7- 1894. Identification of novel HCV NS3 helicase inhibitors through the application of optimized unwinding and ATPase assays in high throughput screens (HTS). K. Kossen; J. Kraemer; D. Winkler; T. Hesterkamp; S. Misialek; R. Rajagopalan; B. O. Buckman; L. M. Blatt; S. Seiwert; L. Beigelman